Literature DB >> 25333695

Origins of the specificity of inhibitor P218 toward wild-type and mutant PfDHFR: a molecular dynamics analysis.

Sheenu Abbat1, Vaibhav Jain, Prasad V Bharatam.   

Abstract

Molecular dynamics simulations were performed to evaluate the origin of the antimalarial effect of the lead compound P218. The simulations of the ligand in the cavities of wild-type, mutant Plasmodium falciparum Dihydrofolate Reductase (PfDHFR) and the human DHFR revealed the differences in the atomic-level interactions and also provided explanation for the specificity of this ligand toward PfDHFR. The binding free energy estimation using Molecular Mechanics Poisson-Boltzmann Surface Area method revealed that P218 has higher binding affinity (~ -30 to -35 kcal/mol) toward PfDHFR (both in wild-type and mutant forms) than human DHFR (~ -22 kcal/mol), corroborating the experimental observations. Intermolecular hydrogen bonding analysis of the trajectories showed that P218 formed two stable hydrogen bonds with human DHFR (Ile7 and Glu30), wild-type and double-mutant PfDHFR's (Asp54 and Arg122), while it formed three stable hydrogen bonds with quadruple-mutant PfDHFR (Asp54, Arg59, and Arg122). Additionally, P218 binding in PfDHFR is stabilized by hydrogen bonds with residues Ile14 and Ile164. It was found that mutant residues do not reduce the binding affinity of P218 to PfDHFR, in contrast, Cys59Arg mutation strongly favors inhibitor binding to quadruple-mutant PfDHFR. The atomistic-level details explored in this work will be highly useful for the design of non-resistant novel PfDHFR inhibitors as antimalarial agents.

Entities:  

Keywords:  MM-PBSA; Plasmodium falciparum DHFR; human DHFR; molecular docking; molecular dynamics; molecular recognition interactions; normal mode analysis

Mesh:

Substances:

Year:  2014        PMID: 25333695     DOI: 10.1080/07391102.2014.979231

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  5 in total

1.  Decreased Susceptibility to Dihydrofolate Reductase Inhibitors Associated With Genetic Polymorphisms in Ugandan Plasmodium falciparum Isolates.

Authors:  Oriana Kreutzfeld; Patrick K Tumwebaze; Oswald Byaruhanga; Thomas Katairo; Martin Okitwi; Stephen Orena; Stephanie A Rasmussen; Jennifer Legac; Melissa D Conrad; Sam L Nsobya; Ozkan Aydemir; Jeffrey A Bailey; Maelle Duffey; Roland A Cooper; Philip J Rosenthal
Journal:  J Infect Dis       Date:  2022-02-15       Impact factor: 7.759

Review 2.  Alternatives to currently used antimalarial drugs: in search of a magic bullet.

Authors:  Akshaya Srikanth Bhagavathula; Asim Ahmed Elnour; Abdulla Shehab
Journal:  Infect Dis Poverty       Date:  2016-11-04       Impact factor: 4.520

Review 3.  Recent Developments and Applications of the MMPBSA Method.

Authors:  Changhao Wang; D'Artagnan Greene; Li Xiao; Ruxi Qi; Ray Luo
Journal:  Front Mol Biosci       Date:  2018-01-10

4.  First-in-human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection.

Authors:  M Farouk Chughlay; Emilie Rossignol; Cristina Donini; Myriam El Gaaloul; Ulrike Lorch; Simon Coates; Grant Langdon; Tim Hammond; Jörg Möhrle; Stephan Chalon
Journal:  Br J Clin Pharmacol       Date:  2020-02-12       Impact factor: 4.335

Review 5.  Driving antimalarial design through understanding of target mechanism.

Authors:  Petar P S Calic; Mahta Mansouri; Peter J Scammells; Sheena McGowan
Journal:  Biochem Soc Trans       Date:  2020-10-30       Impact factor: 5.407

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.